Blood Screening Market 2019: Opportunity and Growth Analysis By Enzo Biochem Inc., Meridian Bioscience, Inc. , BD , Bio-Rad Laboratories, Thermo Fisher Scientific Inc., BioMérieux SA, Beckman Coulter &Others

Global blood screening market is expected to reach a healthy CAGR of 9.7% in the forecast period of 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Competitive Analysis: Global Blood Screening Market

Some of the prominent participants operating in this market are Enzo Biochem Inc., Meridian Bioscience, Inc. , BD , Bio-Rad Laboratories, Inc. , Thermo Fisher Scientific Inc., BioMérieux SA, Beckman Coulter, Inc., Abbott , F. Hoffmann-La Roche Ltd , Cepheid , GRIFOLS INTERNATIONAL, S.A. , Siemens AG , Ortho Clinical Diagnostics , Immucor, Inc., Hologic Inc., among others.

Download Sample PDF Copy of Report https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-blood-screening-market

Segmentation: Global Blood Screening Market

Global blood screening market is categorized based on basis of products & services, technology, disease type and end user.

On the basis of product & services the market is segmented into reagents and kits, instruments and software & services. Reagents and kits are further sub segmented into NAT reagents & kits, ELISA reagents & kits others as well. NAT reagents is further sub segmented into enzymes and polymerases, standards and controls, probes and primers, buffers, nucleotides and solutions alsolabeling and detection reagents. ELISA reagents & kits is further sub segmented into immunosorbents, controls, conjugates (antigen or antibody-conjugated enzyme), substrates (of enzymes) also sample diluents and wash solutions. Instruments segment is further segmented into instruments, product types and instruments, purchase type. In 2017, reagents & kits segment is expected to dominate the global blood screening market growing at the CAGR of 9.4% in the forecast period of 2018 to 2025.

In January 2017, F. Hoffmann-La Roche Ltd launched haematology testing solution. This solution is called the cobas m 511 integrated haematology analyser. This launch marked the entry for Roche Diagnostics in the haematology market.

On the basis of technology the market is segmented into nucleic acid test, enzyme-linked immunosorbent assay (ELISA), rapid tests, western blot assay, next-generation sequencing (NGS) and others. Nucleic acid test is further sub segmented into transcription-mediated amplification (TMA) and real-time polymerase chain reaction (PCR). Enzyme-linked immunosorbent assay (ELISA) is further segmented into ELISA market, by platform, ELISA market, by generation. ELISA Market, By Platform is further sub segmented into chemiluminescence immunoassay (CLIA), fluorescence immunoassay (FIA) and colorimetric immunoassay (CI). ELISA market, by generation is further segmented into first-generation ELISA, second-generation ELISA, third-generation ELISA and fourth-generation and above. In 2017, enzyme-linked immunosorbent assay (ELISA) segment is expected to dominate the global blood screening market growing at the CAGR of 9.8% in the forecast period of 2018 to 2025.

In September 2018, Thermo Fisher Scientific Inc. (U.S.), signed a definitive agreement with BD This business combines a strong technical service program with a variety of media and other products. This acquisition helped company to expand their business on global level with larger number of products.

On the basis of disease type, the market is segmented into respiratory diseases, diabetes mellitus, oncology, cholesterol, HIV/AIDS, cold & flu, infectious diseases and others. In 2017, oncology segment is expected to dominate the global blood screening marketgrowing at the highest CAGR of 10.3% in the forecast period of 2018 to 2025.

In June 2018, Thermo Fisher Scientific (U.S.) launched Oncomine TCR Beta-SR Assay. It is a new next-generation sequencing (NGS) solution in the field of immuno-oncology research. This helped company to expand their business by enhancing their product portfolio.

On the basis of end user the market is segmented into hospitals, clinics, diagnostic centers, blood bank and ambulatory surgical cenetrs. In 2017, diagnostic centers segment is expected to dominate the global blood screening market growing at the highest CAGR of 10.4%in the forecast period of 2018 to 2025.

In September 2016, Siemens Healthineers (Germany) acquired Conworx Technology GmbH (Germany) for point-of-care device interfaces and data management solutions. The company’s products and solutions designed helped in increasing efficiency and to reduce costs.

Drivers: Global Blood Screening Market

RISE IN THE DEMAND OF BLOOD DONATIONS AND BLOOD DONORS:

Blood transfusion is an essential component of the health care field. It helps in saving millions of lives every year in both cases of routine and emergency conditions. Below mentioned are some of the statistics for blood donation and blood donors:

According to the World Health Organization (WHO), in 2017, it was reported that 112.5 million blood donations were collected from worldwide in which approximately half of the blood was collected from developed countries.

According to the World Health Organization (WHO), in 2017, it was reported that in 1000 people, the blood donation rate was 32.1 from high-income countries, 14.9 in upper-middle-income countries, 7.8 in lower-middle-income countries and 4.6 in low-income countries.

According to Australia Red cross blood service, 606,000 donors are there in Australia which are in 1,000 locations such as collection centres for blood donation available.

Restraints:

LACK OF USING NAT TECHNLOGY IN EMERGING COUNTRIES

Nucleic acid amplification technology (NAT) is helpful in determining safety and efficiency of mini-pool testing for various health related problems such as hepatitis C virus (HCV), human immunodeficiency virus (HIV) and other diseases.

In June 2014, a paper published by National Center for Biotechnology Information (NCBI), NAT is one of the advanced techniques, highly sensitive and has issues of high cost related to an infrastructure facility, equipment, consumables lacking in technical expertise for developing countries.

In April 2018, article published by Indian Journal of Pathology and Microbiology, in India, 10 × 10^6 units of blood collected every year. If the whole collected blood is NAT tested then the country will experience an additional cost of 30 × 10^7. The 3 × 10^8 means 300 million US dollar which is a much higher amount for the developing country to afford.

HIGH COST OF TECHNOLOGY AND INSTRUMENTS

A blood screening is a process where blood is tested to detect particular disease in humans. This screening process is carried out in clinical diagnostics specifically for the detection of diseases such as HIV, infection and many other problems related to human health.

Several equipments used such as immunoassay analyzers, chemistry analyzers, assay kits, andhaematology analyzers for the detection of various blood screening process. Specialized analyzers are used to perform assays which are less commonly performed. Typically assay kits are used as standard lab equipments such as a spectrophotometer, and other equipments for ELISA process. Blood Screening Instruments have high cost and also requires maintenance after some period of time.

Merck KGaA (Germany) provides Acetate Colorimetric Assay Kit can be used for 100 colorimetric tests cost for USD 560.615 dollar which is costly to perform tests in laboratory in low income countries. This test is useful for detection of acetate in serum, plasma and animal tissues.

Emerging Alternative Technologies

There are two alternative technologies for performing blood screening including gel test and solid-phase assays. These assays have emerged by providing accurate, reproducible blood bank testing. Both technologies provide increased safety along with decreased biohazardous waste. These technologies are fully automated that decreases the opportunities for human errors and other tasks during test performance.

Food and Drug Administration has provided approval for Gel technology which is used for ABO grouping including forward and reverse, Rh typing, antibody screening and identification.

Solid-phase technology is the Food and Drug Administration (FDA) approved technology for antibody identification, antibody screening and compatibility testing. The screening process i.e. solid phase technology is recommended for antibody detection of transfusion recipients.

Serologic screening is another alternative for the screening process that helps in diagnosing infectious diseases in the microbiology laboratory and other labs .

In July 2016, according to NCBI, 7 out of 4583 (0.15%) from Minnesota, 38 out of 13,757 (0.28%) of the donors from country New York and 11 out of 8363 (0.13%) from New Mexico were found repeat reactive by EIA. The serologic technology includes EIA technique which provides screening.

Multiple Marker Screening (MMS) is also an alternative technology into blood screening that measures specific substances in the blood of a pregnant woman’s mainly from a fetus and the placental tissue. According to The Trustees of the University of Pennsylvania, the MMS test detects about 80% of Down syndrome,

Inquire Regarding This Report https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-blood-screening-market

Opportunity: Global Blood Screening Market

INCREASING MICROBIOLOGY SCREENING & MULTIPLEXING

The screening of blood involves the process that ensures whether the blood collected from people are safe or not. Based on the results of the screening, collected blood units are released for clinical research purpose or discarded if it has some contamination of bacteria or viruses or any other. For performing such screening there are different assays that help in determining the proper result.

Further with advancement, many of the other techniques are introduced with high benefits helping the market to grow in the upcoming days. The techniques are microbial screening and multiplexing technology.

Thermo Fisher Scientific (U.S.) provides microbial isolation and screening which include blood culture systems, clinical microbial identification, and microbiology specimen collection

In August 2015, Eurofins (France) launched accredited NGS tests useful for the identification of non-targeted microorganism. It helps in 16S rDNA screening for identifying the presence of microorganism communities in sample.

In July 2017, July 18, 2017–BD (Becton, Dickinson and Company) (U.S.) introduced new technologies which can automatically report and release negative urine cultures. This technology is transformed in the form of microbiology urine testing.

Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: Corporatesales@databridgemarketresearch.com

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

This release was published on openPR.